Article

Genentech, Alcon 'Best Companies to Work For'

Fortune magazine has named Genentech and Alcon Laboratories to its latest "100 Best Companies to Work For" list.

New York-Fortune magazine has named Genentech and Alcon Laboratories to its latest "100 Best Companies to Work For" list.

South San Francisco, CA-based Genentech, with almost 11,000 employees in the United States, is fifth in the 2008 rankings. The achievement marks the company's 10th consecutive year on the list, a distinction that cannot be claimed by any other biotechnology company, according to Genentech.

This year marks Alcon Laboratories' 10th consecutive time on the list, too. The company, with almost 6,000 employees in the United States, ranks 60th on the 2008 list, five spots up from last year. Alcon Laboratories noted that Fortune cited the company's retirement program, which matches employee contributions 2.4:1, as well as its benefits package, financial compensation, and U.S. headquarters campus in Fort Worth, TX.

The full list appears in the Feb. 4 issue of Fortune magazine and is available at http://www.fortune.com/bestcompanies/.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.